Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Baker Hughes Co (BKR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Baker Hughes Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Baker Hughes Co trades at $58.37 (market cap $57.10B). The key difference: Baker Hughes Co is the larger of the two by market cap, and Baker Hughes Co pays a 1.6% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BKR | |
|---|---|---|
Market Cap | $39.89B | $57.10B |
Sector | Health | Energy |
52-Week High | $491.22 | $69.67 |
52-Week Low | $278.09 | $38.68 |
Enterprise Value | $38.15B | $58.50B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Baker Hughes (BKR) trades at $57.56, up 0.63% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with P/E of 18.39, ROE of 17.14%, and consistent revenue growth from $21.2B in 2022 to $27.7B in 2025. Recent contract wins with Cheniere and Kodiak Gas Services highlight expansion in LNG and power infrastructure, supporting long-term growth prospects.
BKR presents a compelling investment case with analyst consensus price target of $73.45 (27% upside) and 66.7% buy ratings. Key opportunities include LNG infrastructure expansion and energy transition projects, while risks involve oil price volatility and execution of the $13.6B Chart Industries acquisition. The stock's current valuation appears reasonable given earnings growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →
